This page provides a list of some of the company’s key events in the near future. An Investor Relations calendar can be found here.
Herantis Pharma Plc commences a directed share issue, contemplates secondary listing on Nasdaq First North Growth Market Sweden and expands its management teamRead more
Herantis Pharma publishes newsletter for September-OctoberRead more
Herantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
Patient recruitment has been completed and the medical device used in injecting CDNF has been implanted in 17 patients with Parkinson's. The trial continues to proceed as anticipated.Read more
Herantis Pharma publishes newsletter for July-August
We were honored to participate in the Neurotrophic factors and Parkinson’s meeting. Dr. Hartiala was awarded EURAP's best presentation when presenting our Lymfactin® clinical study in April....Read more
Herantis Pharma Plc announces half year financial report January 1 – June 30, 2019 (unaudited)
The Company’s financial position in the last half-year period is solid. The company continues to discuss collaboration opportunities with potential partners for its drug development...Read more
Herantis Pharma publishes newsletter for May-June
We shared our progress in the development of Lymfactin® with several key opinion leaders at the EURAPS 2019 meeting. Read also about our greetings from the Bio€quity meeting!Read more
Public materials related to our company and products will be presented on this page. Presentations in Finnish language can be found here. Please note that these presentations are provided for historical use only. Herantis will not keep these presentations up-to-date after their actual presenting date.
Did you know that Bioethics is a very broad and challenging branch of science with potentially significant impact on our future?
The big difference in biotech investments compared to more established businesses is that you need to assess a possible future success rather than consider existing cash flow and profit.
Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?
Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?
The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.
The development of new drugs is always risky. The more innovative an approach is the higher are the risks. For a real breakthrough in an unmet clinical need, high risk acceptance is needed.
Seppo Nieminen, a Parkinson's patient active in the regional Parkinson's group of Keski-Uusimaa in Finland, gives his thoughts on the current publishing practice on news in Parkinson's.